Insight

Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC

Martin Zapata Laguado/LinkedIn

Jun 2, 2025, 06:19

Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC

Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:

“ASCO 2025 update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembrolizumab adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.”

ASCO 2025 cancer ccRCC Martina Zapata Laguado OncoDaily Oncology renal cell carcinoma

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Blog Posts

Aug 18, 2025, 18:20

Amol Akhade: Key Late-Breaking and Practice-Changing Trials to Watch at WCLC 2025

Insight

Aug 18, 2025, 18:09

Hung Trinh Highlights Pasritamig, a First-in-Class T-Cell Engager for Prostate Cancer

Voices

Aug 18, 2025, 17:43

Building a Healthier Future for Women Also Means Building a Healthier Future for the Next Generation - Elekta Foundation

Voices

Aug 18, 2025, 17:35

Mandar Muzumdar: The Evolution of Single-Cell 3D Genomes in KRAS-Driven Cancers

Blog Posts

Aug 18, 2025, 17:21

Douglas Flora: Create the Things You Wish Existed

Blog Posts

Aug 18, 2025, 17:13

Matt Yurgelun: Thrilled to Be Joining The Jimmy Fund Radio-Telethon

Voices

Aug 18, 2025, 17:04

Striking out Cancer for Patients Like Charlie - The Jimmy Fund

Insight

Aug 18, 2025, 16:52

Darren Haywood: Pleased to Receive COSA Endorsement of the MASCC COG-IMPACT Tool

Science

Aug 18, 2025, 16:48

Petros Grivas: Highlighting Intra-Patient Tumor Heterogeneity in Prostate Cancer Research

Science

Aug 18, 2025, 16:46

How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? - Oncogene Cancer Research

Blog Posts

Aug 18, 2025, 16:37

Amanda Impellizzeri: What a Weekend at the Carolina Cancer Conference

Science

Aug 18, 2025, 16:33

Maria Tolia: New Study on Cardio-Oncology Considerations for Breast Cancer